Skip to main content

Table 1 Baseline characteristics of the spirometry substudy

From: The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes

Characteristic

Tiotropium Respimat® 5 μg (n = 461)

Tiotropium Respimat® 2.5 μg (n = 464)

Tiotropium HandiHaler® 18 μg (n = 445)

Male sex, %

63.6

62.9

59.3

Age, years

65.3 ± 9.1

65.6 ± 9.1

65.8 ± 8.4

Current smoker, %

39.9

40.1

33.3

Smoking history, pack-year

49.7 ± 27.7

51.0 ± 28.6

50.1 ± 28.9

FEV1, L

1.256 ± 0.445

1.215 ± 0.479

1.203 ± 0.489

FEV1, % predicteda

49.31 ± 12.99

48.26 ± 13.47

48.28 ± 13.63

FVC, L

2.555 ± 0.743

2.517 ± 0.796

2.482 ± 0.858

FEV1/FVC ratio, %

49.5 ± 11.0

48.4 ± 11.5

48.6 ± 11.2

GOLD Stage, %

   

 FEV1/FVC ≥70 %

1.3

1.7

2.0

 I

0.7

0.0

0.2

 II

49.2

46.1

42.9

 III

40.8

42.0

44.3

 IV

8.0

10.1

10.3

Any respiratory medication, %

95.7

95.0

97.8

 Anticholinergics

69.2

69.6

69.0

 LABAb

66.6

66.2

67.9

 ICSb

60.1

61.2

62.0

  1. aPost-bronchodilator
  2. bUsed alone or in combination
  3. Abbreviations: COPD chronic obstructive pulmonary disease, FEV 1 forced expiratory volume in 1 second, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, LABA long-acting β2-agonist